48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)

Detalles Bibliográficos
Autores principales: Arastéh, K, Ward, A, Plettenberg, A, Livrozet, JM, Cordes, C, Winston, A, Wang, E, Quinson, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The International AIDS Society 2010
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113048/
http://dx.doi.org/10.1186/1758-2652-13-S4-P45
_version_ 1782205876208140288
author Arastéh, K
Ward, A
Plettenberg, A
Livrozet, JM
Cordes, C
Winston, A
Wang, E
Quinson, A
author_facet Arastéh, K
Ward, A
Plettenberg, A
Livrozet, JM
Cordes, C
Winston, A
Wang, E
Quinson, A
author_sort Arastéh, K
collection PubMed
description
format Online
Article
Text
id pubmed-3113048
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher The International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-31130482011-06-13 48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION) Arastéh, K Ward, A Plettenberg, A Livrozet, JM Cordes, C Winston, A Wang, E Quinson, A J Int AIDS Soc Poster Presentation The International AIDS Society 2010-11-08 /pmc/articles/PMC3113048/ http://dx.doi.org/10.1186/1758-2652-13-S4-P45 Text en Copyright ©2010 Arastéh et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Presentation
Arastéh, K
Ward, A
Plettenberg, A
Livrozet, JM
Cordes, C
Winston, A
Wang, E
Quinson, A
48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
title 48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
title_full 48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
title_fullStr 48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
title_full_unstemmed 48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
title_short 48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
title_sort 48-week efficacy and safety of transitioning virologically stable hiv-1 patients from nevirapine ir 200 mg bid to nevirapine xr 400 mg qd (tranxition)
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113048/
http://dx.doi.org/10.1186/1758-2652-13-S4-P45
work_keys_str_mv AT arastehk 48weekefficacyandsafetyoftransitioningvirologicallystablehiv1patientsfromnevirapineir200mgbidtonevirapinexr400mgqdtranxition
AT warda 48weekefficacyandsafetyoftransitioningvirologicallystablehiv1patientsfromnevirapineir200mgbidtonevirapinexr400mgqdtranxition
AT plettenberga 48weekefficacyandsafetyoftransitioningvirologicallystablehiv1patientsfromnevirapineir200mgbidtonevirapinexr400mgqdtranxition
AT livrozetjm 48weekefficacyandsafetyoftransitioningvirologicallystablehiv1patientsfromnevirapineir200mgbidtonevirapinexr400mgqdtranxition
AT cordesc 48weekefficacyandsafetyoftransitioningvirologicallystablehiv1patientsfromnevirapineir200mgbidtonevirapinexr400mgqdtranxition
AT winstona 48weekefficacyandsafetyoftransitioningvirologicallystablehiv1patientsfromnevirapineir200mgbidtonevirapinexr400mgqdtranxition
AT wange 48weekefficacyandsafetyoftransitioningvirologicallystablehiv1patientsfromnevirapineir200mgbidtonevirapinexr400mgqdtranxition
AT quinsona 48weekefficacyandsafetyoftransitioningvirologicallystablehiv1patientsfromnevirapineir200mgbidtonevirapinexr400mgqdtranxition

Ejemplares similares